Parabolic Drugs Ltd. announced unaudited standalone earnings results for the second quarter and six months ended September 30, 2017. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 239.6 million against INR 141.4 million a year ago. Loss before extraordinary items and tax was INR 137.8 million against INR 416.2 million a year ago. Net Loss after tax from continuing operation was INR 142.3 million compared to INR 431.7 million a year ago. Basic and diluted loss per share was INR 2.30 per share compared to INR 6.97 per share a year ago. For the six months, the company reported net sales/income from operations (net of excise duty) of INR 392.9 million against INR 249.8 million a year ago. Loss before extraordinary items and tax was INR 259.4 million against INR 1,189.9 million a year ago. Net Loss after tax from continuing operation was INR 268.4 million compared to INR 1,204.3 million a year ago. Basic and diluted loss per share was INR 4.34 per share compared to INR 19.46 per share a year ago.